Factors Influencing Aerodynamic Particle Size Distribution of Suspension Pressurized Metered Dose Inhalers

AAPS PharmSciTech

Volumn 16, Issue 1, 2014, Pages 192-201

  Sheth, Poonam ^a   Stein, Stephen W ^b   Myrdal, Paul B ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b 3M COMPANY   (United States)

Author keywords

aerodynamic particle size distribution (APSD); formulation; pressurized metered dose inhaler (pMDI); suspension

Indexed keywords

ALCOHOL; NORFLURANE; SALBUTAMOL SULFATE; AEROSOL; COLLOID; SALBUTAMOL;

AERODYNAMIC PARTICLE SIZE DISTRIBUTION; ANALYTIC METHOD; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; MATHEMATICS; METERED DOSE INHALER; MONTE CARLO METHOD; PARTICLE SIZE; PREDICTION; PRIORITY JOURNAL; SUSPENSION; ADMINISTRATION AND DOSAGE; AEROSOL; ATMOSPHERIC PRESSURE; CHEMICAL MODEL; CHEMISTRY; COLLOID; COMPUTER SIMULATION; DEVICE FAILURE ANALYSIS; EQUIPMENT DESIGN; FLOW KINETICS; PRESSURE; PROCEDURES; SYNTHESIS;

AEROSOLS; AIR PRESSURE; ALBUTEROL; COLLOIDS; COMPUTER SIMULATION; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; METERED DOSE INHALERS; MODELS, CHEMICAL; PARTICLE SIZE; PRESSURE; RHEOLOGY;

EID: 84925461496     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0210-z     Document Type: Article

References (11)

1. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005–15 μm. J Aerosol Sci. 1986;17(5):811–25.
2. Sheth P, Stein SW, Myrdal PB. The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers. Int J Pharm. 2013;455:57–65.
3. Gonda I. Development of a systematic theory of suspension inhalation aerosols. I. A framework to study the effects of aggregation on the aerodynamic behaviour of drug particles. Int J Pharm. 1985;27:99–116.
4. Raabe OG. The dilution of monodispersed suspensions for aerosolization. Am Ind Hyg Assoc J. 1968;29:439–43.
5. Stein SW, Sheth P, Karayiannis C, Chiou H, Myrdal PB. Modeling MDI delivery: a priori predictions, empirical models and experiments. Resp Drug Deliv. 2010;1:353–64.
6. Stein SW, Sheth P, Myrdal PB. A model for predicting size distributions delivered from pMDIs with suspended drug. Int J Pharm. 2012;422(1):101–15.
7. Stein SW, Myrdal PB. A theoretical and experimental analysis of formulation and device parameters affecting solution MDI size distributions. J Pharm Sci. 2004;93(8):2158–75.
8. Stein SW. The influence of sample size on the accuracy of particle size distribution measurements. Resp Drug Deliv. 2008;333–336.
9. Jinks PA. Preparation and utility of sub-micron lactose, a novel excipient for HFA MDI suspension formulations. Proceedings of Drug Delivery to the Lungs, 14; 2003.
10. James J, Crean B, Davies M, Toon R, Jinks P, Roberts CJ. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers. Int J Pharm. 2008;361(1):209–21.
11. Stein SW. Estimating the number of droplets and drug particles emitted from MDIs. AAPS PharmSciTech. 2008;9(1):112–5.